Emicizumab
Mechanism :
Emicizumab-kxwh, a humanized monoclonal modified immunoglobulin G4 (IgG4) antibody with a bispecific factor IXa- and factor X-directed antibody, bridges activated factor IX and factor X to restore the function of missing activated factor VIII that is needed for effective hemostasis.
Indication :
Contraindications :
No contraindications.
Dosing :
Subcutaneous:
Initial: 3 mg/kg once weekly for 4 weeks. Maintenance: 1.5 mg/kg once weekly or 3 mg/kg once every 2 weeks or 6 mg/kg once every 4 weeks.
Adverse Effect :
Headache, antibody development, injection site reaction, diarrhea, arthralgia, myalgia, fever.
Interaction :
Anti-inhibitor Coagulant Complex (Human): Emicizumab-kxwh may enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex (Human).
Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.
Hepatic Dose :
Specific guidelines for dosage adjustments in hepatic impairment are not available.